Program
engasertib
Also written as “Engasertib” and “VAD044 Part II”.
Its studies are mostly in Telangiectasia, Hereditary Hemorrhagic, led by Vaderis Therapeutics.
Furthest: phase 3, since Jul 29, 20264 company-led studies, 3 open or runningNext primary completion: Jan 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vaderis Therapeutics | 43 open or running | phase 3since Jul 29, 2026 | May 10, 2022 | Jan 2027phase 2 · NCT05406362 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 10, 2022First study: phase 2 study in Telangiectasia, Hereditary HemorrhagicFirst studyNCT05406362 · 75 enrolled · United States, Belgium, France and more
- Jul 29, 2026Phase 3 study in Telangiectasia, Hereditary HemorrhagicPhase 3 reachedNCT07743671 · 240 planned · United States, Belgium, France and more
- Aug 28, 2026Phase 1 study in Healthy ParticipantsNCT07800429 · 27 enrolled · Germany
- Nov 9, 2026Phase 1 study in Hepatic ImpairmentNCT07939867 · 18 planned
Ahead
- Jan 2027Primary completion: phase 2 study in Telangiectasia, Hereditary HemorrhagicNCT05406362
- Apr 2027Primary completion: phase 1 study in Hepatic ImpairmentNCT07939867
- Jun 2028Primary completion: phase 3 study in Telangiectasia, Hereditary HemorrhagicNCT07743671
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07939867Hepatic Impairment | 1 | Not yet recruiting | Apr 2027 | 18 |
| NCT07800429Healthy Participants · Germany | 1 | Completed | Oct 28, 2026 | 27 |
| NCT07743671Telangiectasia, Hereditary Hemorrhagic · United States, Belgium, France and more | 3 | Recruiting | Jun 2028 | 240 |
| NCT05406362Telangiectasia, Hereditary Hemorrhagic · United States, Belgium, France and more | 2 | Active, not recruiting | Jan 2027 | 75 |
How it is read
Names in the registry
- “Engasertib”, 3 entries
- “VAD044 Part II”, 1 entry
Conditions, from the studies’ own filings
- Telangiectasia, Hereditary Hemorrhagic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.